 |
|
 |
 |

Home > Company Index > Drugs > Biotechnology-Medicine > Targeted Genetics Corporation
 |
Targeted Genetics Corporation |
 |
 |
 |
PROFILE |
 |
Targeted Genetics is putting the bull's-eye on disease. The firm is developing gene therapy products to treat acquired and inherited diseases. Gene therapy involves the insertion of genes into cells to produce proteins necessary in addressing certain disease conditions. The firm concentrates its efforts in two areas: adeno-associated viral (AAV) vectors for cystic fibrosis, HIV, and other diseases, and synthetic vectors for cancer. Subsidiary CellExSys is developing antigen-specific T-cell gene therapies. Targeted Genetics has several products in the pipeline, including treatments for hemophilia, arthritis, and heart disease. Development partners include Celltech Group, Genzyme, and Biogen.
COMPETITION |
 |
GenStar Therapeutics Corporation (GNT)
Genentech, Inc. (DNA)
Millennium Pharmaceuticals, Inc. (MLNM)
|
 |
STOCK ANALYSIS |
 |
FURTHER ANALYSIS
Advanced Charting
Deals
FINANCIAL OVERVIEW |
 |
Fiscal Year-End: December
2000 Sales (mil.): 11.40
1-Yr. Sales Growth: 67.6%
Employees: 132
Revenue per employee: $86,363.64
KEY PEOPLE |
 |
H. Stewart Parker
CEO
CONTACT INFO |
 |
1100 Olive Way, Ste. 100
Seattle, WA 98101
US
Phone: 206-623-7612
Fax: 206-223-0288
Online: Web Site
|
 |
 |
 |
|
Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.
|

|
 |
 |
|
 |